Clinical trials: CAR-T Cells
Ependymoma
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells).
- Trial name
- NCT04903080
- Testing
- HER2 Specific CAR T Cell
- Where
- 13 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Children's Oncology Group
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Dose Optimization Trial of CD19 Redirected Autologous T Cells
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR Zeta and 4-1 BB co-stimulatory domains) of…
- Trial name
- NCT01747486
- Testing
- CART-19
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma, Immune System Diseases
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Trial name
- NCT03672318
- Testing
- CAR138 T Cells
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma or Plasmacytoma
Engineered Dendritic Cell Vaccines for Multiple Myeloma
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac).
- Trial name
- NCT06435910
- Testing
- DC vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
B-ALL
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT04499573
- Testing
- CD19/CD22 CAR-T
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
This is a single dose escalation study to evaluate the safety, efficacy and pharmacokinetics of ThisCART19A (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell Lymphoma.
- Trial name
- NCT05535673
- Testing
- ThisCART19A
- Volunteers
- 15 people
- Sponsor
- Zhengzhou University
Gastric Adenocarcinoma, Pancreatic Cancer
Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors
An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects with Advanced Solid Tumors
- Conditions
- Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05393986
- Testing
- CT048 Autologous Injection (CT048)
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Peking University
Solid Tumors
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with ALPP-positive Advanced Solid Tumors.
- Trial name
- NCT04627740
- Testing
- Retroviral vector-transduced autologous T cells to express anti-ALPP CARs
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xinqiao Hospital of Chongqing
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
This clinical trial evaluates whether prehabilitation with aerobic and resistance exercise improves physical fitness and quality of life outcomes in older patients planning to undergo chimeric antigen receptor (CAR)-T therapy for…
- Trial name
- NCT07045727
- Testing
- Accelerometry, Aerobic Exercise, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
- Trial name
- MM (NCT04960579)
- Testing
- P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
- Where
- 23 sites in United States
- Volunteers
- 275 people
- Sponsor
- Poseida Therapeutics, Inc.
Thrombocytopenia
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
The purpose of this study is to study how avatrombopag (the study drug) may prevent certain side effects in adults with lymphoma and myeloma getting cancer treatment (CAR-T cell therapy).
- Trial name
- CAR-T 002 (NCT07895017)
- Testing
- Avatrombopag
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Virginia
Follicular Lymphoma (FL)
Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma
This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a).
- Trial name
- TC011_FL_201 (NCT07360288)
- Testing
- TC011 single-arm
- Volunteers
- 40 people
- Sponsor
- TICAROS Co., Ltd.
Relapsed Adult ALL, B Cell Leukemia
Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT
The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation.
- Trial name
- NCT04516551
- Testing
- anti-CD19 allo-CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Xinqiao Hospital of Chongqing
Multiple Myeloma, Primary Plasma Cell Leukemia
Study of CT071 Injection in RRMM or PPCL
A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia
- Trial name
- NCT05838131
- Testing
- Experimental: CAR-T cells Infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
CAR-T for R/R B-NHL
This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients.
- Conditions
- Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, CAR - T CD19/CD20/CD22/CD30
- Trial name
- NCT03196830
- Testing
- CAR-T
- Where
- China
- Volunteers
- 168 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment.
- Trial name
- NCT04555551
- Testing
- Infusion of MCARH109 T cells
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lupus Nephritis
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.
- Trial name
- NCT06785519
- Testing
- CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- He Huang
Hidradenitis Suppurativa
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
- Trial name
- Regulate-HS (NCT06361836)
- Testing
- SBT777101
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sonoma Biotherapeutics, Inc.
Malignant Tumor of Pancreas Metastatic to Liver
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure…
- Trial name
- NCT04037241
- Testing
- Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA
- Sponsor
- Sorrento Therapeutics, Inc.
Primary CNS Lymphoma
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
The CAROUSEL Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with relapsed/refractory Primary CNS Lymphoma.
- Trial name
- CAROUSEL (NCT04443829)
- Testing
- CD19CAR T-cells
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.